Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 4/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140467 | 0.82 | SMO (0.52) | SMOFLT1KDRALDH1A1LMNA | |
| SCHEMBL905521 | 0.81 | FLT1 (0.58) | SMOFLT1KDR | |
| SCHEMBL15038338 | 0.79 | SMO (0.46) | SMOFLT1KDRNPC1EGLN1 | |
| SCHEMBL9739181 | 0.76 | ALDH1A1 (0.37) | SMONPC1EGLN1ALDH1A1LMNA | |
| SCHEMBL3078141 | 0.75 | S1PR1 (0.37) | SMOFLT1KDRALDH1A1 | |
| SCHEMBL3598483 | 0.75 | CYP2C19 (0.41) | SMONPC1EGLN1TAAR1KMT2A | |
| SCHEMBL30617025 | 0.75 | SMO (0.42) | SMOFLT1KDRNPC1EGLN1 | |
| SCHEMBL7115917 | 0.75 | SMO (0.44) | SMOFLT1KDRLMNAHPGD | |
| SCHEMBL23886094 | 0.74 | NPC1 (0.39) | SMONPC1EGLN1TAAR1ALDH1A1 | |
| SCHEMBL30020584 | 0.74 | NPC1 (0.39) | SMONPC1EGLN1TAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137162-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-08-01 | — | — | EP | disclosed |
| EP-2137162-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-08-01 | — | — | EP | disclosed |
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| CN-101657430-A | Organic compounds and uses thereof | NOVARTIS AG CH | 2010-02-24 | — | — | CN | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| WO-2010007120-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007120-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| EP-2137162-A1 | ORGANIC COMPOUNDS AND THEIR USES | Novartis Ag (CH) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | SMO, SHH, GLI1 | SMO 1/4885FLT1 1714/4885KDR 2201/4885 |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | SMO, GLI1, SHH | SMO 1/4885FLT1 2671/4885KDR 2539/4885 |
| US-20100069368-A1 | Organic Compounds and Their Uses | SHH, GLI1, VHL | SMO 5/4885FLT1 2643/4885KDR 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.